CoChat

A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer

Open access
Chen, Gang, Gupta, Richa, Petrik, Silvia, Laiko, Marina, Leatherman, James M., Asquith, Justin M., Daphtary, Maithili M., Garrett-Mayer, Elizabeth, Davidson, Nancy E., Hirt, Kellie, Berg, Maureen, Uram, Jennifer N., Dauses, Tianna, Fetting, John, Duus, Elizabeth M., Atay-Rosenthal, Saadet, Ye, Xiaobu, Wolff, Antonio C., Stearns, Vered, Jaffee, Elizabeth M., Emens, Leisha A. · 2014 · Cancer Immunology Research
Cited by 93

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting tumor vaccines are bioactive, but limited by disease burden and immune tolerance. Cyclophosphamide augments vaccine activity in tolerant neu mice and in patients with metastatic breast cancer. HER2-specific monoclonal antibodies (mAb) enhance vaccine activity in neu mice. We hypothesized that cyclophosphamide-modulated vaccination with HER2-specific mAb safely induces relevant HER2-specific immunity in neu mice and patients with HER2+ metastatic breast cancer. Adding both cyclophosphamide and the HER2-specific mAb 7.16.4 to vaccination maximized HER2-specific CD8+ T-cell immunity and tumor-free survival in neu transgenic mice. We, therefore, conducted a single-arm feasibility study of cyclophosphamide, an allogeneic HER2+ GM-CSF–secreting breast tumor vaccine, and weekly trastuzumab in 20 patients with HER2+ metastatic breast cancer. Primary clinical trial objectives were safety and clinical benefit, in which clinical benefit represents complete response + partial response + stable disease. Secondary study objectives were to assess HER2-specific T-cell responses by delayed type hypersensitivity (DTH) and intracellular cytokine staining. Patients received three monthly vaccinations, with a boost 6 to 8 months from trial entry. This combination immunotherapy was safe, with clinical benefit rates at 6 months and 1 year of 55% [95% confidence interval (CI), 32%–77%; P = 0.013] and 40% (95% CI, 19%–64%), respectively. Median progression-free survival and overall survival durations were 7 months (95% CI, 4–16) and 42 months (95% CI, 22–70), respectively. Increased HER2-specific DTH developed in 7 of 20 patients [of whom 4 had clinical benefit (95% CI, 18–90)], with a trend toward longer progression-free survival and overall survival in DTH responders. Polyfunctional HER2-specific CD8+ T cells progressively expanded across vaccination cycles. Further investigation of cyclophosphamide-modulated vaccination with trastuzumab is warranted. (Clinicaltrials.gov identifier: NCT00399529) Cancer Immunol Res; 2(10); 949–61. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-14-0058

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 93

Metadata

Authors
Chen, G., Gupta, R., Petrik, S., Laiko, M., Leatherman, J. M., Asquith, J. M., Daphtary, M. M., Garrett-Mayer, E., Davidson, N. E., Hirt, K., Berg, M., Uram, J. N., Dauses, T., Fetting, J., Duus, E. M., Atay-Rosenthal, S., Ye, X., Wolff, A. C., Stearns, V., Jaffee, E. M., & Emens, L. A.
Venue
Cancer Immunology Research
Published
2014-10-01
Volume
2
Issue
10
Pages
949-961
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2092246818
Cited by
93
References
5
FWCI
4.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. https://app.cochat.ai/papers/10.1158/2326-6066.cir-14-0058
The paper
Chen, G., Gupta, R., Petrik, S., Laiko, M., Leatherman, J. M., Asquith, J. M., Daphtary, M. M., Garrett-Mayer, E., Davidson, N. E., Hirt, K., Berg, M., Uram, J. N., Dauses, T., Fetting, J., Duus, E. M., Atay-Rosenthal, S., Ye, X., Wolff, A. C., Stearns, V., . . . Emens, L. A. (2014). A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-14-0058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.